<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>689</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>14557672</PubmedId>
            <Abstract>We immunized mice with an attenuated (cold-adapted) influenza virus followed by an attenuated vaccinia virus (modified vaccinia virus Ankara), both expressing a CD8(+)-T-cell epitope derived from malaria sporozoites. This vaccination regimen elicited high levels of protection against malaria. This is the first time that the vaccine efficacy of a recombinant cold-adapted influenza virus vector expressing a foreign antigen has been evaluated.</Abstract>
            <ArticleYear>2003</ArticleYear>
            <ArticlePages>11859-66</ArticlePages>
            <ArticleTitle>Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>González-Aseguinolaza</LastName>
                    <ForeName>Gloria</ForeName>
                </Author>
                <Author>
                    <LastName>Nakaya</LastName>
                    <ForeName>Yurie</ForeName>
                </Author>
                <Author>
                    <LastName>Molano</LastName>
                    <ForeName>Alberto</ForeName>
                </Author>
                <Author>
                    <LastName>Dy</LastName>
                    <ForeName>Edward</ForeName>
                </Author>
                <Author>
                    <LastName>Esteban</LastName>
                    <ForeName>Mariano</ForeName>
                </Author>
                <Author>
                    <LastName>Rodríguez</LastName>
                    <ForeName>Dolores</ForeName>
                </Author>
                <Author>
                    <LastName>Rodríguez</LastName>
                    <ForeName>Juan Ramón</ForeName>
                </Author>
                <Author>
                    <LastName>Palese</LastName>
                    <ForeName>Peter</ForeName>
                </Author>
                <Author>
                    <LastName>García-Sastre</LastName>
                    <ForeName>Adolfo</ForeName>
                </Author>
                <Author>
                    <LastName>Nussenzweig</LastName>
                    <ForeName>Ruth S</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Medical &amp; Molecular Parasitology, NYU School of Medicine. Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Protozoan;Epitopes, T-Lymphocyte;Malaria Vaccines;Protozoan Proteins;circumsporozoite protein, Protozoan</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adaptation, Physiological; Animals; Antibodies, Protozoan(blood); CD8-Positive T-Lymphocytes(immunology); Cold Temperature; Disease Models, Animal; Epitopes, T-Lymphocyte(genetics; immunology; metabolism); Female; Genetic Vectors; Humans; Immunization; Immunization, Secondary; Malaria(immunology; prevention &amp; control); Malaria Vaccines(administration &amp; dosage; genetics; immunology); Mice; Mice, Inbred BALB C; Orthomyxoviridae(genetics; immunology); Plasmodium yoelii(genetics; immunology); Protozoan Proteins(genetics; immunology); Recombination, Genetic; Vaccinia virus(genetics; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>77</Volume>
                <Issue>21</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>P. yoelii CS epitope</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SYVPSAEQI</LinearSequence>
                        <StartingPosition>340</StartingPosition>
                        <EndingPosition>348</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAY34563.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>5861</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Text page 11860</LocationOfData>
                <EpitopeId>62751</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <BCellId>1855372</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SYVPSAEQI</LinearSequence>
                                            <StartingPosition>340</StartingPosition>
                                            <EndingPosition>348</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAY34563.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5861</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>384498</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 1x10^6 PFU CA-CS or Flu-ME and 1 dose of 5X10^7 PFU VAC-CS or MVA-CS, administered at a 2-week interval.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with recombinant influenza vaccinia viruses (CA-CS, VAC-CS, MVA-CS) expressing the epitope.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>38</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The antisporozoite antibody titers were very high in all four groups of mice but varied greatly in individual mice within the same group, namely, from 1,600 to 12,800.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Serum</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Polyclonal</AssayedAntibodyPurificationStatus>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>P. yoelii sporozoites</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>5861</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figures 1, 2 and 3</LocationOfData>
                        <TCellId>6749</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SYVPSAEQI</LinearSequence>
                                            <StartingPosition>340</StartingPosition>
                                            <EndingPosition>348</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAY34563.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5861</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>384498</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 1x10^6 PFU CA-CS or Flu-ME and 1 dose of 5X10^7 PFU VAC-CS or MVA-CS, administered at a 2-week interval.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with recombinant influenza vaccinia viruses (CA-CS, VAC-CS, MVA-CS) expressing the epitope.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>10000055</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SYVPSAEQI</LinearSequence>
                                        <StartingPosition>340</StartingPosition>
                                        <EndingPosition>348</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAY34563.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5861</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>By week 3, the number of epitope specific CD8+ T cells decreased rapidly to levels similar to those found in MVA-CS-boosted mice. This response later declined slightly, remaining detectable for up to 120 days.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 3</LocationOfData>
                        <TCellId>1855370</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SYVPSAEQI</LinearSequence>
                                            <StartingPosition>340</StartingPosition>
                                            <EndingPosition>348</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAY34563.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5861</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>384498</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 1x10^6 PFU CA-CS and 1 dose of 5X10^7 PFU VAC-CS or MVA-CS, administered at a 2-week interval.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with recombinant influenza vaccinia viruses (CA-CS, VAC-CS, MVA-CS) expressing the epitope.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SYVPSAEQI</LinearSequence>
                                        <StartingPosition>340</StartingPosition>
                                        <EndingPosition>348</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAY34563.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>5861</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope specific CD8+ T cell number reached a maximum on day 14 when boosting with VAC-CS, and decreased afterward. However, the percentage of epitope specific CD8+ T cells increased gradually from day 5 to at least day 21after boosting with MVA-CS to approximately 30%.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4 and table 1</LocationOfData>
                        <TCellId>1855371</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                                <Age>8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SYVPSAEQI</LinearSequence>
                                            <StartingPosition>340</StartingPosition>
                                            <EndingPosition>348</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>AAY34563.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>5861</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>384498</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 1x10^6 PFU CA-CS or Flu-ME and 1 dose of 5X10^7 PFU VAC-CS or MVA-CS, administered at a 2-week interval.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with recombinant influenza vaccinia viruses (CA-CS, VAC-CS, MVA-CS) expressing the epitope.</ImmunizationComments>
                        </Immunization>
                        <MhcAllele>
                            <MhcAlleleId>124</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>P. yoelii sporozoites</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>5861</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>182</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>20</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>20</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>Immunization with the epitope expressing influenza followed by immunization with the epitope expressed by vaccinia MVA protected all mice from P. yoelii challenge. Boost with vaccinia Ankara (MVA) was more effective than with the Western Reserve strain.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

